Akihiro Ishiguro

Akihiro Ishiguro

Auto-generated profile, based on publicly available information

Akihiro Ishiguro

Pharmaceuticals and Medical Devices Agency Tokyo Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
KMKazuya Maeda
Kazuya Maeda
AHAkihiro Hisaka
Akihiro Hisaka
KIKiyomi Ito
Kiyomi Ito
YOYoshiyuki Ohno
Yoshiyuki Ohno
AIAkihiro Ishiguro
Akihiro Ishiguro
NNNaomi Nagai
Naomi Nagai
During new drug development, clinical drug interaction studies are carried out in accordance with the mechanism of potential drug interactions evaluated by in vitro studies. The obtained information should be provided efficiently to medical experts through package inserts and various information materials after the drug's launch. A recently updated Japanese guideline presents general procedures that are considered scientifically valid at the present moment. In this review, we aim to highlight the viewpoints of the Japanese guideline and enumerate drugs that were involved or are anticipated to be involved in evident pharmacokinetic drug interactions and classify them by their clearance pathway and potential intensity based on systematic reviews of the literature. The classification would be informative for designing clinical studies during the development stage, and the appropriate management of drug interactions in clinical practice.

1 February 2020 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
AIAkihiro Ishiguro
Akihiro Ishiguro
RSReiko Sato
Reiko Sato
NNNaomi Nagai
Naomi Nagai

1 January 2010 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
MTMasahiro Tohkin
Masahiro Tohkin
AIAkihiro Ishiguro
Akihiro Ishiguro
NKNahoko Kaniwa
Nahoko Kaniwa
YSYoshiro Saito
Yoshiro Saito
KKKouichi Kurose
Kouichi Kurose
RHRyuichi Hasegawa
Ryuichi Hasegawa
Severe adverse drug reactions (ADRs) are a major issue for drug therapy because they can cause serious disorders and be life-threatening. Many severe ADRs appear to be idiosyncratic and unpredictable. Genetic factors may underlie susceptibility to severe ADRs, and identification of predisposing genotypes may improve drug therapy by facilitating prescreening of carriers for specific genetic biomarkers. In this review, we clarify the current status of ADRs in Japan from open ADR data sources. Then, we introduce recent progress in the field of pharmacogenetic biomarkers for severe cutaneous ADRs, liver injury, and statin-induced myopathy. Key challenges for discovery of predictable risk alleles for these severe ADRs are also discussed.

19 March 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
KRKelly Reynolds
Kelly Reynolds
Xinning YangXinning Yang
Xinning Yang
SPSheila Annie Peters
Sheila Annie Peters
VSVikram Sinha
Vikram Sinha
HHHelen Heymann
Helen Heymann
RMRajanikanth Madabushi
Rajanikanth Madabushi

1 July 2008 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
AIAkihiro Ishiguro
Akihiro Ishiguro
STSatoshi Toyoshima
Satoshi Toyoshima
YUYoshiaki Uyama
Yoshiaki Uyama
Pharmacogenomics (PGx) has the potential impact to improve drug-development efficiencies and proper usages of drugs in clinical practice. However, in order to translate PGx into practical applications, multidisciplinary challenges, such as cost and time in development, processes of genomic biomarker qualification, PGx test availabilities and reimbursements, and education on PGx, still remain in clinical, pharmaceutical and regulatory settings. Japanese regulatory bodies for drug approval (i.e., Ministry of Health, Labour and Welfare and Pharmaceutical and Medical Devices Agency) have been taking proactive actions, both internally and internationally, toward translating PGx from bench to bedside. In this article, we summarize the current situations and projects in regulatory implementations of PGx in drug administrations in Japan, including activities to promote PGx-based drug/device developments and therapies. Moreover, we also discuss the future tasks for utilization of PGx in drug evaluations and clinical practices.

9 September 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
AIAkihiro Ishiguro
Akihiro Ishiguro
HKHiroyuki Kusuhara
Hiroyuki Kusuhara
EKEmi Kimoto
Emi Kimoto
SMSo Miyoshi
So Miyoshi
KMKatsuhiko Mizuno
Katsuhiko Mizuno
HSHiroshi Suzuki
Hiroshi Suzuki
The measurement of endogenous biomarkers in plasma and urine before and after administration of an investigational drug in a clinical study may provide an early indication of its drug–drug interaction (DDI) potential via a specific pathway. In the first international harmonized guideline on drug interaction studies, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M12, endogenous biomarkers have been recognized as an emerging approach in the transporter‐ and enzyme‐based DDI risk assessment. Clinical Pharmacology Roundtable Conference 2024 held at Pharmaceuticals and Medical Devices Agency (PMDA) brought together experts from regulatory agencies, academia, and industries to discuss potential advantages and challenges of the biomarkers approach in drug development and regulatory decision making. This meeting report facilitates stakeholders involved in drug development in better understanding the utility of biomarker approaches and promotes early implementation of biomarker‐informed DDI evaluation in regulatory use.